Evaluation of pharmaceutical industry-led access programmes: a standardised framework

Pharmaceutical industry-led access programmes are increasing in number and scope worldwide. We present a new standardised framework for evaluation of these programmes that includes three components: a taxonomy of 11 access programme strategies; a series of logic models, one for each strategy and a s...

Full description

Saved in:
Bibliographic Details
Main Authors: Veronika J Wirtz, Peter C Rockers, Richard O Laing, Nancy Scott, Paul Ashigbie, Erin H Lucca, Chukwuemeka Anthony Umeh
Format: Article
Language:English
Published: BMJ Publishing Group 2019-07-01
Series:BMJ Global Health
Online Access:https://gh.bmj.com/content/4/4/e001659.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850104900047863808
author Veronika J Wirtz
Peter C Rockers
Richard O Laing
Nancy Scott
Paul Ashigbie
Erin H Lucca
Chukwuemeka Anthony Umeh
author_facet Veronika J Wirtz
Peter C Rockers
Richard O Laing
Nancy Scott
Paul Ashigbie
Erin H Lucca
Chukwuemeka Anthony Umeh
author_sort Veronika J Wirtz
collection DOAJ
description Pharmaceutical industry-led access programmes are increasing in number and scope worldwide. We present a new standardised framework for evaluation of these programmes that includes three components: a taxonomy of 11 access programme strategies; a series of logic models, one for each strategy and a set of measurement indicators. The logic models describe pathways of potential programme impact. Concepts relevant across a broad range of strategies were prioritised for inclusion in logic models to ensure consistency and to facilitate synthesis and learning across programmes. Each concept has at least one corresponding measurement indicator with metadata that includes the definition, details on how it should be measured and recommended data sources. The framework establishes a shared language for the collection and reporting of meaningful industry-led access programme information. Broad adoption by programme developers and implementing partners in the for-profit sector and beyond could facilitate shared learning on effective strategies and best practices.
format Article
id doaj-art-908f36304e004baf82890f00a54a416d
institution DOAJ
issn 2059-7908
language English
publishDate 2019-07-01
publisher BMJ Publishing Group
record_format Article
series BMJ Global Health
spelling doaj-art-908f36304e004baf82890f00a54a416d2025-08-20T02:39:14ZengBMJ Publishing GroupBMJ Global Health2059-79082019-07-014410.1136/bmjgh-2019-001659Evaluation of pharmaceutical industry-led access programmes: a standardised frameworkVeronika J Wirtz0Peter C Rockers1Richard O Laing2Nancy Scott3Paul Ashigbie4Erin H Lucca5Chukwuemeka Anthony Umeh6Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USADepartment of Global Health, Boston University School of Public Health, Boston, Massachusetts, USADepartment of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA1 Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA1 Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA1 Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA1 Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USAPharmaceutical industry-led access programmes are increasing in number and scope worldwide. We present a new standardised framework for evaluation of these programmes that includes three components: a taxonomy of 11 access programme strategies; a series of logic models, one for each strategy and a set of measurement indicators. The logic models describe pathways of potential programme impact. Concepts relevant across a broad range of strategies were prioritised for inclusion in logic models to ensure consistency and to facilitate synthesis and learning across programmes. Each concept has at least one corresponding measurement indicator with metadata that includes the definition, details on how it should be measured and recommended data sources. The framework establishes a shared language for the collection and reporting of meaningful industry-led access programme information. Broad adoption by programme developers and implementing partners in the for-profit sector and beyond could facilitate shared learning on effective strategies and best practices.https://gh.bmj.com/content/4/4/e001659.full
spellingShingle Veronika J Wirtz
Peter C Rockers
Richard O Laing
Nancy Scott
Paul Ashigbie
Erin H Lucca
Chukwuemeka Anthony Umeh
Evaluation of pharmaceutical industry-led access programmes: a standardised framework
BMJ Global Health
title Evaluation of pharmaceutical industry-led access programmes: a standardised framework
title_full Evaluation of pharmaceutical industry-led access programmes: a standardised framework
title_fullStr Evaluation of pharmaceutical industry-led access programmes: a standardised framework
title_full_unstemmed Evaluation of pharmaceutical industry-led access programmes: a standardised framework
title_short Evaluation of pharmaceutical industry-led access programmes: a standardised framework
title_sort evaluation of pharmaceutical industry led access programmes a standardised framework
url https://gh.bmj.com/content/4/4/e001659.full
work_keys_str_mv AT veronikajwirtz evaluationofpharmaceuticalindustryledaccessprogrammesastandardisedframework
AT petercrockers evaluationofpharmaceuticalindustryledaccessprogrammesastandardisedframework
AT richardolaing evaluationofpharmaceuticalindustryledaccessprogrammesastandardisedframework
AT nancyscott evaluationofpharmaceuticalindustryledaccessprogrammesastandardisedframework
AT paulashigbie evaluationofpharmaceuticalindustryledaccessprogrammesastandardisedframework
AT erinhlucca evaluationofpharmaceuticalindustryledaccessprogrammesastandardisedframework
AT chukwuemekaanthonyumeh evaluationofpharmaceuticalindustryledaccessprogrammesastandardisedframework